Zhejiang Wecome Pharmaceutical Company Limited (SHE:300878)
China · Delayed Price · Currency is CNY 30.28
-1.64 (-5.14%)
May 12, 2026, 3:04 PM CST
SHE:300878 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 225.16 | 225.27 | 347.01 | 514.56 | 529.41 | 631.18 |
Other Revenue | - | - | 4.19 | 5.07 | 3.03 | 1.77 |
| 225.16 | 225.27 | 351.2 | 519.62 | 532.44 | 632.95 | |
Revenue Growth (YoY) | 1.87% | -35.86% | -32.41% | -2.41% | -15.88% | 1.64% |
Cost of Revenue | 149.6 | 155.29 | 223.4 | 257.69 | 219.08 | 204.38 |
Gross Profit | 75.56 | 69.98 | 127.8 | 261.93 | 313.36 | 428.57 |
Selling, General & Admin | 133.81 | 147.61 | 261.73 | 249.42 | 230.39 | 294.74 |
Research & Development | 8.77 | 9.37 | 14.19 | 42.8 | 39.32 | 37.02 |
Other Operating Expenses | -0.7 | -1.4 | 10.23 | 1.07 | -17.9 | 4.8 |
Operating Expenses | 141.88 | 155.58 | 289.32 | 281.83 | 259.12 | 344.96 |
Operating Income | -66.32 | -85.6 | -161.53 | -19.9 | 54.24 | 83.62 |
Interest Expense | - | - | -9.34 | -9.45 | -5.41 | -2.16 |
Interest & Investment Income | 0.26 | - | 94.26 | 14.56 | 17.04 | 5.55 |
Other Non Operating Income (Expenses) | -23.51 | -13.79 | -0.07 | -0.09 | -0.16 | -0.09 |
EBT Excluding Unusual Items | -89.57 | -99.38 | -76.67 | -14.88 | 65.71 | 86.91 |
Impairment of Goodwill | - | - | -7.76 | -0.14 | -0.22 | -0.08 |
Gain (Loss) on Sale of Investments | -12.48 | -12.48 | - | 4.56 | - | - |
Gain (Loss) on Sale of Assets | -0.82 | -0.99 | -0.47 | -0.01 | -0.63 | 0.07 |
Asset Writedown | -97.67 | -95.62 | -76.26 | -0.52 | -0.18 | -0.02 |
Other Unusual Items | - | - | 2.89 | 4.3 | -1.52 | 13.16 |
Pretax Income | -200.54 | -208.48 | -158.28 | -6.68 | 63.15 | 100.03 |
Income Tax Expense | 17.64 | 21.26 | -13.4 | 0.42 | 13.67 | 3.48 |
Earnings From Continuing Operations | -218.18 | -229.73 | -144.88 | -7.1 | 49.48 | 96.55 |
Minority Interest in Earnings | 2.44 | 2.39 | -2.55 | -1.85 | -0.67 | -0.05 |
Net Income | -215.74 | -227.34 | -147.43 | -8.95 | 48.81 | 96.5 |
Net Income to Common | -215.74 | -227.34 | -147.43 | -8.95 | 48.81 | 96.5 |
Net Income Growth | - | - | - | - | -49.42% | -28.95% |
Shares Outstanding (Basic) | 145 | 145 | 143 | 149 | 144 | 144 |
Shares Outstanding (Diluted) | 145 | 145 | 143 | 149 | 144 | 144 |
Shares Change (YoY) | 0.99% | 1.17% | -4.09% | 3.96% | -0.32% | 19.60% |
EPS (Basic) | -1.49 | -1.57 | -1.03 | -0.06 | 0.34 | 0.67 |
EPS (Diluted) | -1.49 | -1.57 | -1.03 | -0.06 | 0.34 | 0.67 |
EPS Growth | - | - | - | - | -49.25% | -40.59% |
Free Cash Flow | -1.62 | -0.08 | -154.1 | -81 | -28.21 | -238.84 |
Free Cash Flow Per Share | -0.01 | -0.00 | -1.08 | -0.54 | -0.20 | -1.66 |
Dividend Per Share | - | - | 0.140 | 0.250 | - | 0.300 |
Dividend Growth | - | - | -44.00% | - | - | -46.00% |
Gross Margin | 33.56% | 31.06% | 36.39% | 50.41% | 58.85% | 67.71% |
Operating Margin | -29.45% | -38.00% | -45.99% | -3.83% | 10.19% | 13.21% |
Profit Margin | -95.82% | -100.92% | -41.98% | -1.72% | 9.17% | 15.25% |
Free Cash Flow Margin | -0.72% | -0.04% | -43.88% | -15.59% | -5.30% | -37.73% |
EBITDA | -2.29 | -22.72 | -103.25 | 26.75 | 84.04 | 97.65 |
EBITDA Margin | -1.02% | -10.08% | -29.40% | 5.15% | 15.78% | 15.43% |
D&A For EBITDA | 64.03 | 62.88 | 58.28 | 46.65 | 29.8 | 14.03 |
EBIT | -66.32 | -85.6 | -161.53 | -19.9 | 54.24 | 83.62 |
EBIT Margin | -29.45% | -38.00% | -45.99% | -3.83% | 10.19% | 13.21% |
Effective Tax Rate | - | - | - | - | 21.64% | 3.48% |
Revenue as Reported | - | - | 351.2 | 519.62 | 532.44 | 632.95 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.